Decision Regret in Patients with Localised Prostate Cancer: A Systematic Review and Meta-analysis.

Decision regret Prognostic factors Prostate cancer Quality of life

Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 12 10 2022
revised: 17 01 2023
accepted: 15 02 2023
pubmed: 5 3 2023
medline: 5 3 2023
entrez: 4 3 2023
Statut: ppublish

Résumé

Treatment choice for localised prostate cancer remains a significant challenge for patients and clinicians, with uncertainty over decisions potentially leading to conflict and regret. There is a need to further understand the prevalence and prognostic factors of decision regret to improve patient quality of life. To generate the best estimates for the prevalence of significant decision regret localised prostate cancer patients, and to investigate prognostic patient, oncological, and treatment factors associated with regret. We performed a systematic search of MEDLINE, Embase, and PsychINFO databases including studies evaluating the prevalence or patient, treatment, or oncological prognostic factors in localised prostate cancer patients. A pooled prevalence of significant regret was calculated with the formal prognostic factor evaluation conducted per factor identified. Significant decision regret was present in a pooled 20% (95% confidence interval 16-23) of patients across 14 studies and 17883 patients. This was lower in active surveillance (13%), with little difference between those who underwent radiotherapy (19%) and those who underwent prostatectomy (18%). Evaluation of individual prognostic factors demonstrated higher regret in those with poorer post-treatment bowel, sexual, and urinary function; decreased involvement in the decision-making process; and Black ethnicity. However, evidence remains conflicting, with low or moderate certainty of findings. A significant proportion of men experience decision regret after a localised prostate cancer diagnosis. Monitoring those with increased functional symptoms and improving patient involvement in the decision-making process through education and decision aids may reduce regret. We looked at how common regret in treatment decisions is after treatment for early-stage prostate cancer and factors linked with this. We found that one in five regret their decision, with those who had experienced side effects or were less involved in the decision-making process more likely to have regret. By addressing these, clinicians could reduce regret and improve quality of life.

Identifiants

pubmed: 36870852
pii: S2588-9311(23)00037-8
doi: 10.1016/j.euo.2023.02.005
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

456-466

Informations de copyright

Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Jack B Fanshawe (JB)

Guy's and St Thomas' NHS Trust, London, UK. Electronic address: jack.fanshawe@nhs.net.

Vinson Wai-Shun Chan (V)

Royal Derby Hospital, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK; Division of Surgery and Interventional Sciences, University College London, London, UK.

Aqua Asif (A)

Division of Surgery and Interventional Sciences, University College London, London, UK; Royal Surrey NHS Foundation Trust, Surrey, UK.

Alexander Ng (A)

Division of Surgery and Interventional Sciences, University College London, London, UK; Royal Free London NHS Foundation Trust, London, UK.

Mieke Van Hemelrijck (M)

Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

Paul Cathcart (P)

Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.

Ben Challacombe (B)

Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.

Christian Brown (C)

Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.

Rick Popert (R)

Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.

Oussama Elhage (O)

Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London, King's Health Partners, London, UK.

Kamran Ahmed (K)

MRC Centre for Transplantation, Guy's Hospital Campus, King's College London, King's Health Partners, London, UK; Department of Urology, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates; Khalifa University, Abu Dhabi, United Arab Emirates.

Oliver Brunckhorst (O)

MRC Centre for Transplantation, Guy's Hospital Campus, King's College London, King's Health Partners, London, UK.

Prokar Dasgupta (P)

Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK; MRC Centre for Transplantation, Guy's Hospital Campus, King's College London, King's Health Partners, London, UK.

Classifications MeSH